A study found that a medication similar to Viagra slowed cognitive decline in Alzheimer’s patients by 31%. The drug, AR1001, is a phosphodiesterase-5 inhibitor that increases blood flow to the brain. The results were presented at a conference in Boston and were described as "very promising" by experts.
Alzheimer’s disease is expected to affect 153 million people worldwide by 2050. AR1001 showed significant results in patients not taking other Alzheimer’s drugs, but not in those who were.
Experts called for further trials and emphasized the need for scrutiny by the scientific community and drug regulatory bodies before AR1001 can be prescribed.
This summary was written with AI assistance from the original article and may leave out important context. The original reporting belongs to The Guardian · Health. Check the original, and official sources, before acting on any detail.